1. Home
  2. DRH vs PHVS Comparison

DRH vs PHVS Comparison

Compare DRH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

HOLD

Current Price

$12.72

Market Cap

2.5B

Sector

Real Estate

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$37.10

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRH
PHVS
Founded
2004
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
DRH
PHVS
Price
$12.72
$37.10
Analyst Decision
Buy
Buy
Analyst Count
10
11
Target Price
$10.38
$41.82
AVG Volume (30 Days)
2.6M
618.6K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
3.51%
N/A
EPS Growth
144.44
N/A
EPS
0.51
N/A
Revenue
$1,120,491,000.00
N/A
Revenue This Year
$3.44
N/A
Revenue Next Year
$2.42
N/A
P/E Ratio
$24.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$20.65
52 Week High
$13.79
$38.13

Technical Indicators

Market Signals
Indicator
DRH
PHVS
Relative Strength Index (RSI) 53.87 59.27
Support Level $9.10 $24.73
Resistance Level $13.79 N/A
Average True Range (ATR) 0.28 1.75
MACD 0.00 0.15
Stochastic Oscillator 77.55 77.78

Price Performance

Historical Comparison
DRH
PHVS

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: